<DOC>
	<DOCNO>NCT02255760</DOCNO>
	<brief_summary>This Phase 1 , randomize , double-blind , placebo-controlled , dose escalation study evaluate safety tolerability single ascend IV dose MEDI3902 healthy adult subject 18 60 year age .</brief_summary>
	<brief_title>Phase 1 Randomized Double-blind Placebo Controlled Study Evaluate Safety PK MEDI3902 Healthy Adults</brief_title>
	<detailed_description>This Phase 1 , randomize , double-blind , placebo-controlled , dose escalation study evaluate safety tolerability single ascend IV dose MEDI3902 healthy adult subject 18 60 year age . Approximately 40 subject enrol across 4 fix dose cohort 1 study site . This study last approximately 90 day , constitute screen period 28 day , 1 day investigational product administration , 60 day safety follow period .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<criteria>1 . Age 18 60 year time screen 2 . Written inform consent 3 . Weight ≥ 45 kg ≤ 110 kg screen 4 . Healthy medical history , physical examination , baseline safety laboratory study 5 . Systolic blood pressure ( BP ) &lt; 140 mm Hg diastolic BP &lt; 90 mm Hg screen 6 . Electrocardiogram ( ECG ) without clinically significant abnormality screen 7 . Able complete followup period Day 61 require protocol 1 . Acute ( timelimited ) illness , include fever 99.5F , day prior day plan dose 2 . Any drug therapy within 7 day prior Day 1 ( except contraceptive single use acetaminophen , aspirin , antihistamine , combination overthecounter ( OTC ) product contain acetaminophen antihistamine , OTC nonsteroidal anti inflammatory agent dose equal low recommend package ) . Vitamins nutritional supplement newly introduce , ie , take least 30 day prior enrollment , exclusionary 3 . Blood drawn excess total 450 mL ( 1 unit ) reason within 2 month prior screen 4 . Receipt immunoglobulin blood product within 6 month prior screen 5 . Receipt investigational product precede 90 day expect receipt investigational product period study followup , concurrent participation another interventional study Receipt vaccine within 7 day prior investigational product dosing plan receipt within 61 day investigational product dose except influenza vaccine administer least 28 day dose 6 . Previous receipt mAb 7 . Immunodeficiency due illness , include human immunodeficiency virus ( HIV ) infection , due drug , include course glucocorticoid therapy exceed 2 week prednisone equivalent dose 20 mg daily every day within 6 month prior screen . HIV test must negative screen 8 . History allergic disease reaction likely exacerbate component investigational product 9 . Either history active infection hepatitis B C 10 . Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , serum creatinine upper limit normal ( ULN ) hemoglobin , white blood cell count , platelet count lower limit normal screen predose blood sample 11 . Pregnant nursing mother 13 . History alcohol drug abuse within past 2 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>MEDI3902 , Safety , Pharmacokinetics</keyword>
</DOC>